![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C31H44F3N5O6 |
Molar mass | 639.717 g·mol−1 |
3D model (JSmol) | |
| |
|
Leritrelvir (RAY1216) is an antiviral drug which acts as a 3C-like protease inhibitor. It was developed and approved [1] in China for treatment of COVID-19. [2] [3] [4] [5]